Palvella Therapeutics Financials - Benzinga

Palvella Therapeutics Inc

PVLANASDAQ

Trade with Public

Trade with Public

$152.28

-4.96-3.15%

At close: Sep 4, 5:00 PM EST

$153.05

-4.19-2.66%

Pre-Market: 5:26 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Palvella Therapeutics Financials

Palvella Therapeutics (PVLA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Palvella Therapeutics Q2 EPS $(1.52) Misses $(1.14) Estimate

Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.52) per share which missed the analyst consensus estimate of $(1.14) by 33.33 percent. This is a 76.74 percent decrease over losses of $(0.86) per

Benzinga Newsdesk

PRO
Palvella Therapeutics Q1 EPS $(1.20) Misses $(0.93) Estimate

Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.20) per share which missed the analyst consensus estimate of $(0.93) by 29.03 percent. This is a 62.16 percent decrease over losses of $(0.74) per

Benzinga Newsdesk

PRO
Palvella Therapeutics Q4 EPS $(1.08) Misses $(0.91) Estimate

Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.91) by 18.29 percent. This is a 79.89 percent increase over losses of $(5.37) per

Benzinga Newsdesk

Earnings Scheduled For March 31, 2026

Benzinga Insights

Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December

Avi Kapoor

PRO
Palvella Therapeutics Q3 EPS $(1.03) Misses $(0.83) Estimate

Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.03) per share which missed the analyst consensus estimate of $(0.83) by 23.5 percent. This is a 73.86 percent increase over losses of $(3.94) per share

Benzinga Newsdesk